The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2013Development of G2019S Selective LRRK2 Inhibitors for the Treatment of Parkinson’s Disease
Objective/Rationale:
The LRRK2 kinase has been implicated as a potential therapeutic target for the treatment of Parkinson’s disease (PD). The goal of this project is to make experimental... -
Rapid Response Innovation Awards, 2013Evaluation of Targeted Plasticity Therapy as a Treatment for Motor Dysfunction in Parkinson’s Disease
Objective/Rationale:
Deterioration of motor function is a debilitating symptom of Parkinson’s disease (PD). We have recently developed a novel method that utilizes stimulation of the...
-
MJFF Research Grant, 2013Specific Modulation of Tau Oligomers by Passive Immunotherapy in a Parkinson's Disease Model
Objective/Rationale:
The accumulation of tau protein is an important pathogenic factor in Parkinson’s disease (PD) and other neurodegenerative disorders. Our recent findings from pre-clinical models... -
LRRK2 Challenge, 2013In Vivo Rescue of Dopamine Release Deficits via Kinase Inhibition in LRRK2 Mutant Mice
Objective/Rationale:
Abnormal kinase activity is thought to be responsible for the pathogenic effects of LRRK2 in parkinsonian patients and many lines of evidence point towards a role of... -
Research Grant, 2013Validation of Blood-borne Autoantibody Biomarkers for Parkinson’s Disease Supplement
Promising Outcomes of Original Grant:
The purpose of the original study was to determine if a small group of selected blood-borne autoantibody biomarkers that were previously shown to be effective in... -
Research Grant, 2013Six-month Oral Toxicity Study of the Accordion Pill™ of Carbidopa/Levodopa
Objective/Rationale:
The Accordion Pill™ is designated to significantly stabilize the pharmacokinetic profile of drugs with a narrow absorption window, such as levodopa. Regular controlled-release...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.